Overview

Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal dose of PAC113 mouthrinse for treatment of oral candidiasis in HIV seropositive patients.
Phase:
Phase 2
Details
Lead Sponsor:
Pacgen Biopharmaceuticals Corporation
Collaborator:
Quintiles, Inc.